Better Therapeutics EBIT

The latest EBIT for MCAD is $-32M as of September 2023. That compares with $-42M in the prior-year period — up 24.1% year over year. That is above the sector sector average of $-63M. Investors often review this figure alongside Better Therapeutics's historical trend and sector peers before judging valuation or financial health.

Over the past year, MCAD's EBIT moved from $-42M to $-32M — a 24.1% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Better Therapeutics's operating scale or balance-sheet position.

Against its sector companies, MCAD currently prints $-32M for EBIT, while the sector average sits near $-63M. That is roughly 49.0% above the sector mean. Large gaps often invite a closer look at Better Therapeutics's growth, margins, and balance sheet.

A EBIT figure of $-32M for MCAD is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. The sector average is about $-63M. Explore the charts below for those layers of context.

After noting MCAD's EBIT ($-32M), review year-over-year change from $-42M, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.